Floatz logo

EXEMESTANE

HER2-negative Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
65/ 100

Competitive context

135 Active assets in the HER2-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
Kristina A. Fanucci
Phase 4BB
Irinotecan
GI Innovation, Inc.
Phase 4BB
FULVESTRANT
Olema Pharmaceuticals, Inc.
Phase 4BB
(+)-VINCRISTINE
GI Innovation, Inc.
Phase 4BB
Ribociclib
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →